By Wu Tsai Neurosciences Institute at Stanford University, Nicholas Weiler
From Our Neurons to Yours is a show that crisscrosses scientific disciplines to bring you to the frontiers of brain science, produced by the Wu Tsai Neurosciences Institute at Stanford University.
... more
5
1818 ratings
The podcast currently has 43 episodes available.
In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.
Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.
Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.
Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer’s therapies, as growing biological understanding of Alzheimer’s risk and resilience bear fruit with promising new approaches to treatment.
Learn More:
Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.
Amyloid Drug Skepticism:
Alzheimer's Genetics Research:
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Getting help for depression can be like purgatory. Setting aside for a moment the stigma and other barriers to seeking treatment in the first place, finding the right combination of medication and/or therapy can be a months- or years-long process of trial and error. And for about one third of people, nothing seems to work.
Today we're talking with Dr. Leanne Williams, the founding director of the Stanford Center for Precision Mental Health and Wellness and Vincent V.C. Woo Professor in the Stanford Department of Psychiatry and Behavioral Sciences.
Williams and her team have recently used brain imaging and machine learning techniques to identify six distinct "biotypes" of depression — each of which may require a different approach to treatment. Beyond setting the stage for more targeted therapies, better understanding the biology behind the disease could finally cut through the stigma of one of the world's most common brain disorders.
Learn more
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Today, we're talking with Stanford neuro-oncologist, Michelle Monje. This is actually the third time we've had Michelle on the show, in part because she's been a pioneer of three exciting frontiers in neuroscience — so far!
This week, we're going to talk about cancer neuroscience. Michelle founded this new field with her discovery that deadly brain tumors not only link up physically with the healthy brain tissue surrounding them, but the cancers actually need the brain's electrical activity to grow and spread.
It turns out that many cancers — not only in the brain — depend on nervous system innervation for their survival. Understanding this dependent relationship better may present an exciting new line of attack for oncology.
Join us to learn more!
News coverage
Relevant Publications
Review Articles
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
This week on From Our Neurons to Yours, we're talking about using new techniques for growing human brain tissue in the lab to solve a rare neurological disorder.
Host Nicholas Weiler sits down with Sergiu Pasca an innovative Stanford scientist who has developed groundbreaking technologies to grow human brain tissue in the lab, creating "organoids" and "assembloids" that model brain disorders like autism and schizophrenia.
Pasca describes the process of turning patient skin cells into embryo-like stem cells and then into functional brain cells that can live and develop for over two years, and even be transplanted into rat brains to study their growth and development.
It may sound like science fiction, but these techniques represent a major step toward understanding and treating complex neurological conditions such as Timothy syndrome, a rare genetic disorder whose biology Pasca has spent the past 15 years unraveling.
Join us for fascinating glimpse into the future of developmental neuroscience and potential for new therapies for our remarkable self-assembling brains.
Learn more
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Today, we're going to talk about virtual reality and how it could be used to treat depression.
We're talking with psychiatrist Kim Bullock, the founding director of Stanford's Neurobehavioral Clinic and Virtual Reality & Immersive Technologies (VRIT) program.
Dr. Bullock — a physician certified in Neuropsychiatry, Psychiatry, and Lifestyle Medicine — calls herself a "radical behaviorist." Like other practitioners of cognitive behavioral therapy (CBT), she sees the troublesome thoughts and emotional states of many psychiatric disorders as just another form of behavior, which can be reshaped through self awareness and practice — much like you might work at avoiding junk food or not biting your nails.
Of course, one of the biggest challenges is the practice part. It's no easy task for patients to practice experiencing the world in a more positive, healthy way. This is why Bullock is eager for practitioners of CBT and related forms of psychotherapy to embrace virtual reality technologies — which enable psychiatrists to prescribe precisely calibrated "experiences" to treat cognitive & behavioral disorders.
We started by discussing early results from a clinical trial for a virtual reality-enhanced intervention major depressive disorder, which Dr. Bullock recently launched with support from the Wu Tsai Neurosciences Institute Neuroscience:Translate program.
Join us to learn more about how VR is transforming the world of psychotherapy!
Learn More
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
This week, we're diving into recent research that sheds light on a new form of brain plasticity involving changes in the insulation of nerve fibers — called myelin. It turns out that myelin plasticity is implicated in a number of serious conditions, from epilepsy to drug abuse and addiction.
We're excited to bring back two previous guests on the show to share their insights on this previously unknown form of plasticity: Stanford psychiatry professor Rob Malenka (S1 E1 - Psychedelics and Empathy), a pioneer in the study of synaptic plasticity and addiction, and neuro-oncologist Michelle Monje (S1 E12 - Brain Fog), who made some of the very first observations of myelin plasticity in the brain, essentially founding this field.
Together, they discuss their recent findings on the role of myelin plasticity in opioid addiction and its implications for understanding addictive behaviors.
Get ready to nerd out as we uncover a new angle on our brain's remarkable capacity for change.
Learn More
Myelination in the brain may be key to ‘learning’ opioid addiction | Stanford Medicine (2024)
Adaptive and maladaptive myelination in health and disease | Nature Reviews Neurology (2022)
Brain plasticity promotes worsening of epileptic seizures, study finds | Stanford Medicine (2022)
The Brain Learns in Unexpected Ways | Scientific American (2020)
Brain boosting: It's not just grey matter that matters | New Scientist (2015)
Neural activity promotes brain plasticity through myelin growth, researchers find | News Center | Stanford Medicine (2014)
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
-- We're re-releasing our conversation with Carla Shatz, one of our favorites from the archive, which comes up all the time on the show in the context of brain plasticity and aging. Enjoy, and see you next time! -NW --
When we're kids, our brains are amazing at learning. We absorb information from the outside world with ease, and we can adapt to anything. But as we age, our brains become a little more fixed. Our brain circuits become a little less flexible.
You may have heard of a concept called neuroplasticity, our brain's ability to change or rewire itself. This is of course central to learning and memory, but it's also important for understanding a surprisingly wide array of medical conditions, including things like epilepsy, depression, even Alzheimer's disease.
Today's guest, Carla Shatz, is a pioneer in understanding how our brains are sculpted by our experiences. She's credited with coining the phrase neurons that fire together, wire together. Her work over the past 40 years is foundational to how we understand the brain today.
So I was excited to talk to Shatz about our brain's capacity for change, and I started off by asking about this sort of simple question, why exactly do we have this learning superpower as kids to do things like pick up languages and why does it go away?
Shatz is Sapp Family Provostial Professor of Biology and of Neurobiology and the Catherine Holman Johnson director of Stanford Bio-X.
Learn More
Episode Credits
This episode was produced by Webby award-winning producer Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Hi everyone — quick programming announcement. As we head into summer, we'll be moving to an every-other-week cadence as we prepare more conversations from the frontiers of neuroscience. I'm very excited about what we're working on for you, so stay tuned!
In the meantime, we'd love to hear from you! Email us at [email protected] with your thoughts, praise, critiques, or just to say hello.
That's all for now. See you next time!
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
The powerful new generation of AI tools that has come out over the past few years — DALL-E, ChatGPT, Claude, Gemini, and the rest — have blown away our old ideas about what AI can do and raised questions about what it means for computers to start acting... intelligent?
This week, we ask what the rise of these systems might teach us about our own biological intelligence — and vice versa. What does modern neuroscience have to say about how AI could become as flexible, efficient, and resilient as the human brain.
Few people are better positioned to speak to the intersection of neuroscience and AI than today's guest: Surya Ganguli.
Ganguli's lab produced some of the first diffusion models — which are at the foundation of today's AI revolution — and is now working to understand how complex emergent properties arise from biological and artificial neural networks.
Ganguli is a member of the Neuroscience Theory Center at the Wu Tsai Neurosciences Institute, a Senior Fellow at Stanford's Institute for Human-Centered Artificial Intelligence (HAI), and an associate professor in Stanford's Department of Applied Physics.
Further Reading
Visit us!
Want to learn more about AI and Neuroscience? Join us at Wu Tsai Neuro's annual symposium on October 17, 2024, which will showcase the frontiers of biological and artificial intelligence research. (More details coming soon!)
Episode credits
This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute.
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
The podcast currently has 43 episodes available.
5,788 Listeners
32,034 Listeners
858 Listeners
26,045 Listeners
960 Listeners
433 Listeners
43,330 Listeners
6,428 Listeners
10,474 Listeners
3,977 Listeners
2,057 Listeners
5,187 Listeners
12,957 Listeners
416 Listeners